Barclays PLC Makes New Investment in CeriBell (NASDAQ:CBLL)

Barclays PLC bought a new position in shares of CeriBell (NASDAQ:CBLL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,190 shares of the company’s stock, valued at approximately $497,000. Barclays PLC owned about 0.05% of CeriBell as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in CeriBell during the 4th quarter worth about $32,000. Summit Investment Advisors Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $33,000. PNC Financial Services Group Inc. bought a new stake in shares of CeriBell during the fourth quarter worth approximately $47,000. Corebridge Financial Inc. acquired a new position in CeriBell in the fourth quarter valued at approximately $158,000. Finally, Wells Fargo & Company MN bought a new position in CeriBell in the fourth quarter valued at approximately $167,000.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CBLL. LADENBURG THALM/SH SH initiated coverage on CeriBell in a research note on Friday, April 4th. They issued a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group restated a “buy” rating and set a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.50.

Insider Activity at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the company’s stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the sale, the chief executive officer now directly owns 727,151 shares of the company’s stock, valued at approximately $10,987,251.61. This represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 24,700 shares of company stock valued at $372,434.

CeriBell Stock Up 6.8 %

Shares of CBLL stock opened at $17.10 on Friday. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The stock’s fifty day moving average is $18.21.

CeriBell (NASDAQ:CBLL) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. On average, research analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.